PFIZER INC Payments for (Proceeds from) Short-term Investments
PFIZER INC (PFE) reported Payments for (Proceeds from) Short-term Investments of -$6.92 billion for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForProceedsFromShortTermInvestments · last filed 2020-02-27
- PFIZER INC payments for (proceeds from) short-term investments for the quarter ending 2019-12-31 was $1.38B, a 67.88% decline year-over-year.
- PFIZER INC payments for (proceeds from) short-term investments for the quarter ending 2019-09-29 was -$3.59B, a 524.35% decline year-over-year.
- PFIZER INC payments for (proceeds from) short-term investments for the quarter ending 2019-06-30 was $1.22B, a 62.64% decline year-over-year.
- PFIZER INC payments for (proceeds from) short-term investments for the quarter ending 2019-03-31 was -$5.94B.
- PFIZER INC payments for (proceeds from) short-term investments for fiscal 2019 was -$6.92B, a 276.79% decline from fiscal 2018.
- PFIZER INC payments for (proceeds from) short-term investments for fiscal 2018 was $3.92B.
- PFIZER INC payments for (proceeds from) short-term investments for fiscal 2017 was -$2.06B, a 148.79% decline from fiscal 2016.
- PFIZER INC payments for (proceeds from) short-term investments for fiscal 2016 was $4.22B.
| Period end | Payments for (Proceeds from) Short-term Investments 3 month | Payments for (Proceeds from) Short-term Investments 6 month | Payments for (Proceeds from) Short-term Investments 9 month | Payments for (Proceeds from) Short-term Investments 12 month |
|---|---|---|---|---|
| 2019-12-31 | $1.38B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$2.21B derived: sum of 2 quarters · filed 2020-02-27 | -$984.00M derived: sum of 3 quarters · filed 2020-02-27 | -$6.92B 10-K · filed 2020-02-27 |
| 2019-09-29 | -$3.59B derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$2.37B derived: sum of 2 quarters · filed 2019-11-07 | -$8.31B 10-Q · filed 2019-11-07 | -$4.00B derived: sum of 4 quarters · filed 2020-02-27 |
| 2019-06-30 | $1.22B derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$4.72B 10-Q · filed 2019-08-08 | -$415.00M derived: sum of 3 quarters · filed 2020-02-27 | $431.00M derived: sum of 4 quarters · filed 2020-02-27 |
| 2019-03-31 | -$5.94B 10-Q · filed 2019-05-09 | -$1.64B derived: sum of 2 quarters · filed 2020-02-27 | -$793.00M derived: sum of 3 quarters · filed 2020-02-27 | $2.48B derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-12-31 | $4.30B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $5.15B derived: sum of 2 quarters · filed 2020-02-27 | $8.42B derived: sum of 3 quarters · filed 2020-02-27 | $3.92B 10-K · filed 2020-02-27 |
| 2018-09-30 | $846.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $4.12B derived: sum of 2 quarters · filed 2019-11-07 | -$385.00M 10-Q · filed 2019-11-07 | $315.00M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-07-01 | $3.28B derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$1.23B 10-Q · filed 2019-08-08 | -$531.00M derived: sum of 3 quarters · filed 2020-02-27 | $135.00M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-04-01 | -$4.51B 10-Q · filed 2019-05-09 | -$3.81B derived: sum of 2 quarters · filed 2020-02-27 | -$3.14B derived: sum of 3 quarters · filed 2020-02-27 | -$2.79B derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $700.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $1.37B derived: sum of 2 quarters · filed 2020-02-27 | $1.72B derived: sum of 3 quarters · filed 2020-02-27 | -$2.06B 10-K · filed 2020-02-27 |
| 2017-10-01 | $666.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $1.02B derived: sum of 2 quarters · filed 2018-11-08 | -$2.76B 10-Q · filed 2018-11-08 | $7.95B derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-07-02 | $354.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$3.42B 10-Q · filed 2018-08-09 | $7.28B derived: sum of 3 quarters · filed 2019-02-28 | $545.00M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-04-02 | -$3.78B 10-Q · filed 2018-05-10 | $6.92B derived: sum of 2 quarters · filed 2019-02-28 | $191.00M derived: sum of 3 quarters · filed 2019-02-28 | $933.00M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $10.70B derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $3.97B derived: sum of 2 quarters · filed 2019-02-28 | $4.71B derived: sum of 3 quarters · filed 2019-02-28 | $4.22B 10-K · filed 2019-02-28 |
| 2016-10-02 | -$6.73B derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$5.99B derived: sum of 2 quarters · filed 2017-11-09 | -$6.49B 10-Q · filed 2017-11-09 | -$6.70B derived: sum of 4 quarters · filed 2018-02-22 |
| 2016-07-03 | $742.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $249.00M 10-Q · filed 2017-08-10 | $38.00M derived: sum of 3 quarters · filed 2018-02-22 | -$2.50B derived: sum of 4 quarters · filed 2018-02-22 |
| 2016-04-03 | -$493.00M 10-Q · filed 2017-05-11 | -$704.00M derived: sum of 2 quarters · filed 2018-02-22 | -$3.24B derived: sum of 3 quarters · filed 2018-02-22 | -$1.02B derived: sum of 4 quarters · filed 2018-02-22 |
| 2015-12-31 | -$211.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | -$2.75B derived: sum of 2 quarters · filed 2018-02-22 | -$525.00M derived: sum of 3 quarters · filed 2018-02-22 | -$5.77B 10-K · filed 2018-02-22 |
| 2015-09-27 | -$2.54B derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$314.00M derived: sum of 2 quarters · filed 2016-11-10 | -$5.56B 10-Q · filed 2016-11-10 | -$4.54B derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-06-28 | $2.22B derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | -$3.02B 10-Q · filed 2016-08-11 | -$2.00B derived: sum of 3 quarters · filed 2017-02-23 | -$5.55B derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-03-29 | -$5.24B 10-Q · filed 2016-05-12 | -$4.23B derived: sum of 2 quarters · filed 2017-02-23 | -$7.77B derived: sum of 3 quarters · filed 2017-02-23 | -$7.67B derived: sum of 4 quarters · filed 2017-02-23 |
| 2014-12-31 | $1.01B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | -$2.53B derived: sum of 2 quarters · filed 2017-02-23 | -$2.43B derived: sum of 3 quarters · filed 2017-02-23 | -$3.93B 10-K · filed 2017-02-23 |
| 2014-09-28 | -$3.55B derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | -$3.44B derived: sum of 2 quarters · filed 2015-11-05 | -$4.95B 10-Q · filed 2015-11-05 | -$2.85B derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-29 | $101.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$1.40B 10-Q · filed 2015-08-06 | $701.00M derived: sum of 3 quarters · filed 2016-02-29 | $2.48B derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-30 | -$1.50B 10-Q · filed 2015-05-07 | $600.00M derived: sum of 2 quarters · filed 2016-02-29 | $2.38B derived: sum of 3 quarters · filed 2016-02-29 | -$2.82B derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $2.10B derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $3.88B derived: sum of 2 quarters · filed 2016-02-29 | -$1.32B derived: sum of 3 quarters · filed 2016-02-29 | $4.28B 10-K · filed 2016-02-29 |
| 2013-09-29 | $1.78B derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | -$3.42B derived: sum of 2 quarters · filed 2014-11-06 | $2.18B 10-Q · filed 2014-11-06 | $2.20B derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-06-30 | -$5.20B derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $401.00M 10-Q · filed 2014-08-07 | $425.00M derived: sum of 3 quarters · filed 2015-02-27 | -$2.06B derived: sum of 4 quarters · filed 2015-02-27 |
| 2013-03-31 | $5.60B 10-Q · filed 2014-05-08 | $5.62B derived: sum of 2 quarters · filed 2015-02-27 | $3.14B derived: sum of 3 quarters · filed 2015-02-27 | $4.76B derived: sum of 4 quarters · filed 2015-02-27 |
| 2012-12-31 | $24.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | -$2.46B derived: sum of 2 quarters · filed 2015-02-27 | -$836.00M derived: sum of 3 quarters · filed 2015-02-27 | -$1.46B 10-K · filed 2015-02-27 |
| 2012-09-30 | -$2.48B derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | -$860.00M derived: sum of 2 quarters · filed 2013-11-08 | -$1.48B 10-Q · filed 2013-11-08 | -$1.71B derived: sum of 4 quarters · filed 2014-02-28 |
| 2012-07-01 | $1.62B derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $999.00M 10-Q · filed 2013-08-09 | $773.00M derived: sum of 3 quarters · filed 2014-02-28 | -$1.55B derived: sum of 4 quarters · filed 2014-02-28 |
| 2012-04-01 | -$623.00M 10-Q · filed 2013-05-10 | -$849.00M derived: sum of 2 quarters · filed 2014-02-28 | -$3.17B derived: sum of 3 quarters · filed 2014-02-28 | -$5.51B derived: sum of 4 quarters · filed 2014-02-28 |
| 2011-12-31 | -$226.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | -$2.55B derived: sum of 2 quarters · filed 2014-02-28 | -$4.89B derived: sum of 3 quarters · filed 2014-02-28 | -$10.87B 10-K · filed 2014-02-28 |
| 2011-10-02 | -$2.32B derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | -$4.67B derived: sum of 2 quarters · filed 2012-11-09 | -$10.65B 10-Q · filed 2012-11-09 | |
| 2011-07-03 | -$2.34B derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | -$8.33B 10-Q · filed 2012-08-09 | ||
| 2011-04-03 | -$5.98B 10-Q · filed 2012-05-10 | |||
| 2010-12-31 | -$5.95B 10-K · filed 2013-02-28 | |||
| 2009-12-31 | -$5.78B 10-K · filed 2012-02-28 | |||
| 2008-12-31 | -$7.91B 10-K · filed 2011-02-28 | |||
| 2007-12-31 | -$7.24B 10-K · filed 2010-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |